Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial

Leroi, I., Woolham, J., Gathercole, R., Howard, R., Dunk, B., Fox, C., O'Brien, J., Bateman, A., Poland, F., Bentham, P., Burns, A., Davies, A., Forsyth, K., Gray, R., Knapp, M., Newman, S. P., McShane, R. & Ritchie, C. (2013). Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial. Trials, 14(1), p. 349. doi: 10.1186/1745-6215-14-349

[img]
Preview
Text - Published Version
Available under License Creative Commons: Attribution 2.0.

Download (305kB) | Preview

Abstract

Background: Assistive technology and telecare (ATT) are relatively new ways of delivering care and support to
people with social care needs. It is claimed that ATT reduces the need for community care, prevents unnecessary
hospital admission, and delays or prevents admission into residential or nursing care. The current economic
situation in England has renewed interest in ATT instead of community care packages. However, at present, the
evidence base to support claims about the impact and effectiveness of ATT is limited, despite its potential to
mitigate the high financial cost of caring for people with dementia and the social and psychological cost to unpaid
carers.

Method/design: ATTILA (Assistive Technology and Telecare to maintain Independent Living At Home for People with Dementia) is a pragmatic, multi-centre, randomised controlled trial over 104 weeks that compares outcomes for people with dementia who receive ATT and those who receive equivalent community services but not ATT. The study hypothesis is that fewer people in the ATT group will go into institutional care over the 4-year period for which the study is funded. The study aims to recruit 500 participants, living in community settings, with dementia or significant cognitive impairment, who have recently been referred to social services. Primary outcome measures are time in days from randomisation to institutionalisation and cost effectiveness. Secondary outcomes are caregiver burden, health-related quality of life in carers, number and severity of serious adverse events, and data on acceptability, applicability and reliability of ATT intervention packages. Assessments will be undertaken in weeks 0 (baseline), 12, 24, 52 and 104 or until institutionalisation or withdrawal of the participant from the trial.

Discussion: In a time of financial austerity, CASSRs in England are increasingly turning to ATT in the belief that it will deliver good outcomes for less money. There is an absence of robust evidence for the cost-effectiveness and benefit of using assistive technology and telecare. The ATTILA trial meets a pressing need for robust, generalisable evidence to either justify continuing investment or reappraise the appropriate scale of ATT use.

Item Type: Article
Uncontrolled Keywords: Assistive technology, Telecare, Dementia, Randomised control trial, Independence, Community living
Subjects: R Medicine > RA Public aspects of medicine
R Medicine > RC Internal medicine
Divisions: School of Health Sciences
URI: http://openaccess.city.ac.uk/id/eprint/8095

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics